Lisata Therapeutics Inc Announces Positive FY/24 Results

First Berlin Equity Research has reaffirmed its 'Buy' recommendation for Lisata Therapeutics Inc with a target price of USD 15.00. Lisata's FY/24 financial results surpassed expectations, reporting a revenue of USD 1.0 million from an upfront license fee with Kuva Labs Inc. The company holds USD 31.2 million in cash, deemed sufficient to sustain operations until the second quarter of 2026.

Central to this positive outlook is the progress of Lisata's lead drug candidate, certepetide. It is set to achieve significant development milestones in 2025, spanning seven cancer studies. Recent results from Cohort A of the phase 2b ASCEND study for the treatment of metastatic pancreatic ductal adenocarcinoma were encouraging.

In a strategic move, Lisata has partnered with AI specialist GATC Health to explore the optimal development path for certepetide through AI technology. Stakeholders anticipate a year filled with key developments, potentially boosting Lisata's stock value.